Skip to content
Review Open access

The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact

Sep 2026 · Journal of Immunotherapy and Precision Oncology · Vol 9, pp. 153 - 245 · 1 citation · 724 references
Medicine

TL;DR

This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.

Abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their clinical impact is limited by immune-related adverse events (irAEs), therapeutic resistance, and the lack of reliable predictive biomarkers, contributing to a shift from early promise to a therapeutic plateau. irAEs affect multiple organ systems and may lead to treatment interruption and significant morbidity. Emerging strategies emphasize phenotype-driven and steroid-sparing approaches to control toxicity while preserving antitumor efficacy. Concurrently, primary and acquired resistance remain major challenges, driven by tumor-intrinsic mechanisms, immune microenvironment alterations, and host factors. Furthermore, current biomarkers, including programmed cell death ligand 1 (PD-L1) expression and tumor mutation burden, demonstrate inconsistent predictive performance across tumor types. Advances in immune profiling, genomics, and microbiome research are enabling more precise patient stratification and informing novel therapeutic strategies, including rational combinations and targeted immunomodulation. This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability. Together, these advances position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology. Graphical Abstract

Read PDF

Similar papers

Review Aug 2026

Overcoming Resistance to Immune Checkpoint Blockade: Mechanistic Insights and Emerging Therapeutic Directions.

The central conclusion of this review is that effective clinical translation will necessitate a paradigm shift from discrete pathway inhibition toward integrated precision immuno-oncology strategies that combine molecular profiling, immune-contexture analysis, and mechanism-based combination therapies.

Yu-Yu Xu, Huiling Shen · 0 citations
Review Open access Oct 2026

Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation

This review focuses on targetable biomarker classes that link resistance biology to therapeutic sensitization across cancers, including transcription factors, genomic alterations, immune checkpoint proteins and metabolic regulators, and discusses the mechanistic basis of resistance-associated biomarkers.

Chao Wang, Dong Yang · 0 citations
Review Open access Sep 2026

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

This review examines the evolving landscape of ICI‐based combination therapies, including regimens that combine ICI with chemotherapy, targeted therapy, antibody–drug conjugates, antiangiogenic agents, and radiotherapy, which have expanded first‐line treatment options across multiple solid tumors and, in selected setti...

Qiong-Yue Zhang, Zhi-Lai Qin, Caijuan Guo · 0 citations
Review Oct 2026

Precision toxicity control in checkpoint immunotherapy.

Immune checkpoint inhibitors have changed cancer management. However, immune-related adverse events (irAEs) can disrupt treatment and limit effective combination strategies. The standard of care tends to involve broad immunosuppression, which may compromise antitumor immunity and fail to address the dominant biology of...

Zhen Sun, Xiao-Yi Yang, Wei-Ming Shen et al. · 1 citation
Review Aug 2026

Overcoming resistance to immune checkpoint inhibitors in cancer: translational mechanisms, dynamic biomarkers, clinically actionable combination strategies, and comparative checkpoint biology

This review integrates the major tumor-intrinsic and tumor-extrinsic mechanisms that drive ICI resistance, including defective antigen presentation, impaired interferon signaling, oncogenic and epigenetic immune escape programs, metabolic rewiring, suppressive myeloid and stromal circuits, abnormal vasculature, and pro...

R. Karataş, Yaren Alras, Sarenur Teki̇ner et al. · 0 citations
Review Open access Oct 2026

Overcoming adaptive resistance to cancer immunotherapy: molecular targeting strategies for the tumor microenvironment

ABSTRACT Introduction Immunotherapy resistance is mediated by mechanisms distinct from those underlying conventional chemotherapy, including tumor-intrinsic alterations, an immunosuppressive tumor microenvironment, and other host factors, that collectively constrain durable responses. Areas covered This review provides...

Kenneth K. W. To, Ting-Nan Ma, Long-Ling Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.